Radical prostatectomy is surgery to remove all of the prostate gland and some of the tissue around it, to treat prostate cancer.
Hackensack Meridian Health Bayshore Medical Center in Holmdel is now home to the da Vinci Si Surgical system, bringing advanced technology in surgery to the medical center's operating room and to the community.
Advanced Accelerator Applications S.A., a Novartis company and leader in nuclear medicine theragnostics, today announced that the first patients have been dosed in two Phase I/II clinical studies of radiolabeled PSMA-R2, a urea-based ligand of Prostate-Specific Membrane Antigen, which is commonly expressed on prostate cancer cells.
A new study reveals declines in prostate cancer screening and diagnoses in the United States in recent years, as well as decreases in the use of definitive treatments in men who have been diagnosed.
UCLA researchers have discovered that a combination of high doses of radiotherapy and hormonal therapy provides the best chance of decreasing the mortality rate in men with aggressive prostate cancer.
An Italian study featured in the March issue of The Journal of Nuclear Medicine demonstrates that a novel nuclear medicine imaging agent targeting copper accumulation in tumors can detect prostate cancer recurrence early in patients with biochemical relapse (rising prostate-specific antigen [PSA] level).
Among men with prostate cancer who underwent radical prostatectomy (RP), those who were obese had a higher risk of biochemical recurrence, according to data presented at the American Association for Cancer Research Special Conference Obesity and Cancer: Mechanisms Underlying Etiology and Outcomes, held Jan. 27-30.
You may know that your surgeon is using the latest minimally invasive technology for your surgery, but how do you know if they've mastered it? To help answer that question, researchers at Keck Medicine of USC looked to a custom recording tool similar in concept to a flight recorder on an airplane.
For prostate cancer patients who have rising levels of PSA (a cancer indicator) even after radical prostatectomy, early treatment makes a difference.
Establishing the way in which a genetic alteration called a TMPRSS2-ERG gene fusion forms in a prostate cancer, rather than the presence of the gene fusion itself, could help identify patients with prostate cancer with a low risk of spreading, which might determine the best course of treatment for the patient.
Recognizing that administrative health care databases can be a valuable, yet challenging, tool in the nation's ongoing pursuit of personalized medicine, statisticians Liangyuan Hu and Madhu Mazumdar of the Icahn School of Medicine at Mount Sinai have developed advanced statistical modeling and analytic tools that can make health care and medical data more meaningful.
In the featured article from the February 2017 issue of the Journal of Nuclear Medicine, researchers document the first-in-human application of a new imaging agent to help find prostate cancer in both early and advanced stages and plan treatment.
More than 1,000 patients at Sheffield Teaching Hospitals have now benefitted from a high-tech robot that enables surgeons to perform highly precise and minimally-invasive surgery.
For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track how the tumor progresses.
Prostate-specific antigen (PSA) and other biomarkers are essential tools for diagnosing and monitoring prostate cancer.
A team of Mayo Clinic researchers has, for the first time, successfully mapped patterns of prostate cancer recurrence, following surgery. Using C-11 choline PET imaging and multiparametric MRI, researchers found an anatomically diverse pattern of recurrence, which may help optimize treatment of patients whose prostate cancer returns after surgery.
In the largest study of its kind to date, researchers have identified and validated three distinct molecular subtypes of prostate cancer that correlate with distant metastasis-free survival and can assist in future research to determine how patients will respond to treatment, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology.
While the majority of prostate cancers are slow growing and not fatal, some are aggressive and lethal.
Active surveillance (AS) has become an increasingly important alternative to surgery, chemotherapy, or radiation treatment for men diagnosed with low risk prostate cancer.
Changes in benign tissues next to prostate tumors may provide an early warning for patients at higher risk for biochemical recurrence after a radical prostatectomy, a study by researchers at Case Western Reserve University and Johns Hopkins Medical Institutions shows.
Prostate cancer patients may soon have a new option to treat their disease: laser heat. UCLA researchers have found that focal laser ablation - the precise application of heat via laser to a tumor - is both feasible and safe in men with intermediate risk prostate cancer.